Concurrent delivery of GM‐CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors
- 18 February 2003
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 5 (5) , 386-398
Abstract
Background: The immune resistance of large tumors represents a major problem for cancer immunotherapy, whereas the need for repeated injections of high doses of recombinant anti‐angiogenic proteins represents a similar problem for anti‐angiogenic therapy. To test whether antitumor activity could be increased by combining the above two mechanisms, this study examined the therapeutic effect of combination gene therapy using a murine granulocyte‐macrophage colony‐stimulating factor (mGM‐CSF) gene and a human endostatin (hED) gene on a rat orthotopic liver tumor model.Methods: An adenoviral vector was constructed that simultaneously carried two transcriptional cassettes, for the expression of mGM‐CSF and hED, respectively, or that carried a single cassette of either gene. The adenoviruses were intratumorally administered to 3‐day‐old or 7‐day‐old tumors. Moreover, the antitumor effects of the combination therapy and monotherapy were assessed and compared.Results: The double‐gene‐containing adenoviral vector expressed transgenes as efficiently as the single‐gene‐containing vector. Moreover, the adenovirally expressed endostatin was biologically active, as demonstrated in vitro and in vivo. Results from animal experiments demonstrated a synergistic antitumor effect induced by the combined mGM‐CSF and hED therapy. The combination of hED with mGM‐CSF enhanced tumor‐specific CTL activity, but did not interfere with the infiltration of cellular effectors in the tumor regions. The blood vessel density of the liver tumors markedly reduced as a result of hED expression in both monotherapy and combination therapy. Furthermore, combination therapy significantly increased the number of apoptotic cells in the tumor regions.Conclusions: The experimental results suggest that the combined gene therapy against tumor cells and the tumor vascular system using antitumor immune mechanisms and anti‐angiogenic mechanisms holds promise as a strategy for treating cancers. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Adeno-associated virus–mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivoCancer Gene Therapy, 2002
- In vivo activation of JAK2/STAT‐3 pathway during angiogenesis induced by GM‐CSFThe FASEB Journal, 2001
- Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivoCancer Gene Therapy, 2001
- Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expressionCancer Gene Therapy, 2001
- Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virusCancer Gene Therapy, 2001
- Tumor-Induced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by Cytokine-Secreting Tumor VaccineHuman Gene Therapy, 2000
- Regression of Established Mouse Leukemia by GM-CSF-Transduced Tumor Vaccine: Implications for Cytotoxic T Lymphocyte Responses and Tumor BurdensHuman Gene Therapy, 1997
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Differential Expression of the Common β and Specific α Chains of the Receptors for GM-CSF, IL-3, and IL-5 in Endothelial CellsExperimental Cell Research, 1993
- Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferateNature, 1989